Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
Completed
Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma. This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly. The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2016
Locations: New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico
Conditions: Carcinoma, Non-Small-Cell Lung
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Completed
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may result.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/13/2016
Locations: The University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico
Conditions: Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
Completed
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzyme... Read More
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
01/20/2016
Locations: New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Breast Cancer
Combination Paclitaxel, Carboplatin and Temozolomide
Completed
The purpose of this study is to determine the maximum tolerable dose of temozolomide in combination with fixed dose of paclitaxel and carboplatin and to determine the overall tumor response rate with this combination and to determine the duration of response.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2016
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Lung Diseases, Cancer
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without liposomal doxorubicin in treating recurrent ovarian epithelial or primary peritoneal cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of carboplatin with or without liposomal doxorubicin in treating patients who have recurrent o... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/23/2015
Locations: Veterans Affairs Medical Center - Albuquerque, Albuquerque, New Mexico +1 locations
Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
Terminated
This study is designed to investigate the possibility that use of two similar but distinct drugs used together in treatment of advanced cancer might prove less toxic than either agent used alone, because dosages can be reduced for each agent. This is a phase I study that is designed to measure the frequency and levels of specific side effects when Carboplatin and Pazopanib are used in combination in advanced cancer patients. The possibility that anti-tumor activity will occur is also going to be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2015
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Cancer, Metastatic
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
Completed
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2015
Locations: New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico
Conditions: Non-Small Cell Lung Cancer
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2015
Locations: Pfizer Investigational Site, Albuquerque, New Mexico +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
Completed
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2014
Locations: Saint Joseph Medical Center, Albuquerque, New Mexico
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Combination Chemotherapy in Treating Children With Neuroblastoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/31/2014
Locations: University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico
Conditions: Neuroblastoma
Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/23/2014
Locations: University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico
Conditions: Kidney Cancer
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work in treating children with low-grade astrocytomas or other residual tumors of the brain.
Gender:
ALL
Ages:
9 years and below
Trial Updated:
09/06/2013
Locations: University of New Mexico Cancer Center, Albuquerque, New Mexico
Conditions: Brain Tumors, Central Nervous System Tumors